Details

Autor(en) / Beteiligte

• Papa, Linda
• Akinyi, Linnet
• Liu, Ming Cheng
• Pineda, Jose A
• Tepas, Joseph J
• Oli, Monika W
• Zheng, Wenrong
• Robinson, Gillian
• Robicsek, Steven A
• Gabrielli, Andrea
• Heaton, Shelley C
• Hannay, H Julia
• Demery, Jason A
• Brophy, Gretchen M
• Layon, Joe
• Robertson, Claudia S
• Hayes, Ronald L
• Wang, Kevin K. W

Titel

Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury

Ist Teil von

• Critical care medicine, 2010-01, Vol.38 (1), p.138-144

Ort / Verlag

Hagerstown, MD: by the Society of Critical Care Medicine and Lippincott Williams & Wilkins

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• OBJECTIVE:Ubiquitin C-terminal hydrolase (UCH-L1), also called neuronal-specific protein gene product (PGP 9.3), is highly abundant in neurons. To assess the reliability of UCH-L1 as a potential biomarker for traumatic brain injury (TBI) this study compared cerebrospinal fluid (CSF) levels of UCH-L1 from adult patients with severe TBI to uninjured controls; and examined the relationship between levels with severity of injury, complications and functional outcome. DESIGN:This study was designed as prospective case control study. PATIENTS:This study enrolled 66 patients, 41 with severe TBI, defined by a Glasgow coma scale (GCS) score of ≤8, who underwent intraventricular intracranial pressure monitoring and 25 controls without TBI requiring CSF drainage for other medical reasons. SETTING:Two hospital system level I trauma centers. MEASUREMENTS AND MAIN RESULTS:Ventricular CSF was sampled from each patient at 6, 12, 24, 48, 72, 96, 120, 144, and 168 hrs following TBI and analyzed for UCH-L1. Injury severity was assessed by the GCS score, Marshall Classification on computed tomography and a complicated postinjury course. Mortality was assessed at 6 wks and long-term outcome was assessed using the Glasgow outcome score 6 months after injury. TBI patients had significantly elevated CSF levels of UCH-L1 at each time point after injury compared to uninjured controls. Overall mean levels of UCH-L1 in TBI patients was 44.2 ng/mL (±7.9) compared with 2.7 ng/mL (±0.7) in controls (p <.001). There were significantly higher levels of UCH-L1 in patients with a lower GCS score at 24 hrs, in those with postinjury complications, in those with 6-wk mortality, and in those with a poor 6-month dichotomized Glasgow outcome score. CONCLUSIONS:These data suggest that this novel biomarker has the potential to determine injury severity in TBI patients. Further studies are needed to validate these findings in a larger sample.